Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Description

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Conditions

Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Reduced Dose Hypofractionated Radiotherapy (3Gy X 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): a Multisite Phase 2 Randomized Trial

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Condition
Indolent B-Cell Non-Hodgkin Lymphoma
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224-9980

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥ 18 years
  • * Histological confirmation of indolent B-cell lymphoma that can include any of the following:
  • * Follicular lymphoma (grade 1 or 2 or 3A)
  • * Marginal zone lymphoma (nodal or extranodal)
  • * Any stage disease
  • * Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
  • * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
  • * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
  • * Provide written informed consent
  • * Ability to complete questionnaire(s) by themselves
  • * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
  • * Confirmation from radiation oncologist of suitability to participate in study
  • * Any of the following:
  • * Pregnant women
  • * Nursing women
  • * Men or women of childbearing potential who are unwilling to employ adequate contraception
  • * T-cell lymphoma
  • * Small and chronic lymphocytic lymphoma
  • * Grade 3B follicular lymphoma

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Bradford S. Hoppe, MD, MPH, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-05-30